Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106–16. PubMed PMID: 25104651; eng.
   PubMed Web of Science ®Google Scholar
• Mehta S. Age-related macular degeneration. Prim Care. 2015 Sep;42(3):377–391. PubMed PMID: 26319344; eng
   PubMed Web of Science ®Google Scholar
• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564–572. PubMed PMID: 15078675; eng.
   PubMed Web of Science ®Google Scholar
• Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006 Dec;124(12):1754–1760. PubMed PMID: 17159036.
   PubMedGoogle Scholar
• van Lookeren Campagne M, LeCouter J, Yaspan BL, et al. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014 Jan;232(2):151–164. PubMed PMID: 24105633; eng.
   PubMed Web of Science ®Google Scholar
• Wei CX, Sun A, Yu Y, et al. Challenges in the development of therapy for dry age-related macular degeneration. Adv Exp Med Biol. 2016;854:103–109. PubMed PMID: 26427400; eng
   PubMed Web of Science ®Google Scholar
• Wei Y, Liao H, Ye J. Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration: A PRISMA-compliant network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 May;97(21):e10422. PubMed PMID: 29794727; eng
   PubMed Web of Science ®Google Scholar
• Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018 Jun 1;136(6):666–677. PubMed PMID: 29801123; eng.
   PubMed Web of Science ®Google Scholar
• Kassa E, Ciulla TA, Hussain RM, et al. Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335–342. PubMed PMID: 30686077.
   PubMed Web of Science ®Google Scholar
• Khandhadia S, Cherry J, Lotery AJ. Age-related macular degeneration. Adv Exp Med Biol. 2012;724:15–36. PubMed PMID: 22411231; eng
   PubMed Web of Science ®Google Scholar
• Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012 Jul 12;75(1):26–39. PubMed PMID: 22794258; PubMed Central PMCID: PMCPMC3404137. eng.
   PubMed Web of Science ®Google Scholar
• Knickelbein JE, Chan CC, Sen HN, et al. Inflammatory mechanisms of age-related macular degeneration. Int Ophthalmol Clin. 2015 Summer;55(3):63–78. PubMed PMID: 26035762; PubMed Central PMCID: PMCPMC4472429. eng.
   PubMedGoogle Scholar
• Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008 Feb;49(2):522–527. PubMed PMID: 18234994; eng.
   PubMed Web of Science ®Google Scholar
• Fletcher EL, Jobling AI, Greferath U, et al. Studying age-related macular degeneration using animal models. Optom Vis Sci. 2014 Aug;91(8):878–886. PubMed PMID: 24978866; PubMed Central PMCID: PMCPMC4186726. eng.
   PubMed Web of Science ®Google Scholar
• Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular photocoagulation study group. Arch Ophthalmol. 1986 May;104(5):694–701. PubMed PMID: 2423061; eng.
   PubMedGoogle Scholar
• Battaglia Parodi M, La Spina C, Berchicci L, et al. Photosensitizers and photodynamic therapy: verteporfin. Dev Ophthalmol. 2016;55:330–336. PubMed PMID: 26501167; eng
   PubMedGoogle Scholar
• Kawczyk-Krupka A, Bugaj AM, Potempa M, et al. Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: clinical perspectives. Photodiagnosis Photodyn Ther. 2015 Jun;12(2):161–175. PubMed PMID: 25843911; eng.
   PubMed Web of Science ®Google Scholar
• Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2007 Jul 18;(3):Cd002030. PubMed PMID: 17636693; eng. DOI:10.1002/14651858.CD002030.pub3.
   PubMed Web of Science ®Google Scholar
• Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008 Jul;27(4):372–390. PubMed PMID: 18621565; eng
   PubMed Web of Science ®Google Scholar
• Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014 Mar;7(2):167–180. PubMed PMID: 24483136
   PubMed Web of Science ®Google Scholar
• Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3186–3193. PubMed PMID: 12824270; eng
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419–1431. PubMed PMID: 17021318.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.drugs.com/condition/macular-degeneration.html
   Google Scholar
• Schwartz SG, Scott IU, Flynn HW Jr. et al. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv. 2014 Jan;11(1):61–68. PubMed PMID: 24219407; eng
   PubMed Web of Science ®Google Scholar
• Lai TY, Liu S, Das S, et al. Intravitreal injection–technique and safety. Asia Pac J Ophthalmol (Phila). 2015 Nov-Dec;4(6):321–328. PubMed PMID: 26649760; eng.
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother. 2005 Jul;6(8):1421–1423. PubMed PMID: 16013991; eng
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27):2805–2816. PubMed PMID: 15625332; eng.
   PubMed Web of Science ®Google Scholar
• Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial. Br J Ophthalmol. 2008 Dec;92(12):1606–1611. PubMed PMID: 18614570; PubMed Central PMCID: PMCPMC2584239. eng.
   PubMed Web of Science ®Google Scholar
• Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother. 2008 Feb;9(3):499–508. PubMed PMID: 18220500; eng
   PubMed Web of Science ®Google Scholar
• Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). 2011 Jun;25(6):661–672. PubMed PMID: 21455242; PubMed Central PMCID: PMCPMC3178135. eng
   PubMed Web of Science ®Google Scholar
• Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006 Mar;26(3):262–269. PubMed PMID: 16508424; eng
   PubMed Web of Science ®Google Scholar
• Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014 Oct;74(16):1891–1925. PubMed PMID: 25315029; eng
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005 Jun;112(6):1035–1047. PubMed PMID: 15936441; eng.
   PubMed Web of Science ®Google Scholar
• Dakin HA, Wordsworth S, Rogers CA, et al. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open. 2014 Jul 29;4(7):e005094. PubMed PMID: 25079928; PubMed Central PMCID: PMCPMC4120317. eng.
   PubMed Web of Science ®Google Scholar
• Brechner RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol. 2011 May;151(5):887–895.e1. PubMed PMID: 21310390; eng.
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Decullier E, Souied EH, et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1529–1537. PubMed PMID: 25142373; PubMed Central PMCID: PMCPMC4180904. eng.
   PubMed Web of Science ®Google Scholar
• Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014 Sep 15;(9):Cd011230. PubMed PMID: 25220133; PubMed Central PMCID: PMCPMC4262120. eng. DOI:10.1002/14651858.CD011230.pub2.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Mar;6(2):103–113. PubMed PMID: 23473589; eng
   PubMed Web of Science ®Google Scholar
• Yang J, Wang X, Fuh G, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm. 2014 Oct 6;11(10):3421–3430. PubMed PMID: 25162961; eng.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537–2548. PubMed PMID: 23084240; eng.
   PubMed Web of Science ®Google Scholar
• Ruiz Ramos J, Pascual-Camps I, Cuellar-Monreal MJ, et al. Aflibercept in exudative age related macular degeneration refractory to ranibizumab. Arch Soc Esp Oftalmol. 2015 Dec;90(12):566–571. PubMed PMID: 26515015; eng spa.
   PubMedGoogle Scholar
• Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013 Jul;156(1):29–35.e2. PubMed PMID: 23668679; eng.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Oishi A, Tsujikawa A, et al. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2015 Sep;253(9):1471–1477. PubMed PMID: 25391986; eng.
   Google Scholar
• Wu Z, Zhou P, Li X, et al. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. PLoS One. 2013;8(3):e57642. PubMed PMID: 23469213; PubMed Central PMCID: PMCPMC3587646. eng
   PubMed Web of Science ®Google Scholar
• Liu K, Song Y, Xu G, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2018 Aug 24. DOI:10.1016/j.ajo.2018.08.026. [ PubMed PMID: 30148987; eng].
   Google Scholar
• Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-1). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03577899?term=conbercept+panda&rank=1
   Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999 Sep-Oct;27(5):536–544. PubMed PMID: 10528633; eng.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging. 2013 May;30(5):331–358. PubMed PMID: 23539234; eng
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726–733. PubMed PMID: 15671306; eng.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260–1266. PubMed PMID: 18046235; eng.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007 Dec;114(12):2179–2182. PubMed PMID: 18054637; eng.
   PubMed Web of Science ®Google Scholar
• Niwa Y, Kakinoki M, Sawada T, et al. Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6501–6505. PubMed PMID: 26447985; eng.
   PubMed Web of Science ®Google Scholar
• Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1606–1608. PubMed PMID: 19875666; eng.
   PubMed Web of Science ®Google Scholar
• Christoforidis JB, Briley K, Binzel K, et al. Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model. Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5636–5645. PubMed PMID: 29094168; eng.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012 Oct;154(4):682–686.e2. PubMed PMID: 22818800; eng.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013 Mar 5;54(3):1616–1624. PubMed PMID: 23361508; eng.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao Z, Kaila N, et al. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology. 2014 Nov;121(11):2237–2246. PubMed PMID: 25001159; eng.
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017 Oct;37(10):1847–1858. PubMed PMID: 28106709; PubMed Central PMCID: PMCPMC5642319.
   PubMed Web of Science ®Google Scholar
• Zehetner C, Kralinger MT, Modi YS, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2015 Mar;93(2):e154–9. PubMed PMID: 25488124.
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014 Dec;98(12):1636–1641. PubMed PMID: 25001321; PubMed Central PMCID: PMCPMC4251300.
   PubMed Web of Science ®Google Scholar
• Korf BR. Neurofibromatosis. Handb Clin Neurol. 2013;111:333–340. PubMed PMID: 23622184
   PubMedGoogle Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 Nov;93(11):2645–2668. PubMed PMID: 15389672; eng
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001 Mar;114(Pt 5):853–865. PubMed PMID: 11181169; eng
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012 Jun;15(2):171–185. PubMed PMID: 22302382; PubMed Central PMCID: PMCPMC3338918. eng.
   PubMed Web of Science ®Google Scholar
• Funk M, Karl D, Georgopoulos M, et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology. 2009 Dec;116(12):2393–2399. PubMed PMID: 19815292; eng.
   PubMed Web of Science ®Google Scholar
• Motohashi R, Noma H, Yasuda K, et al. Dynamics of inflammatory factors in aqueous humor during ranibizumab or aflibercept treatment for age-related macular degeneration. Ophthalmic Res. 2017;58(4):209–216. PubMed PMID: 28796997; eng
   PubMed Web of Science ®Google Scholar
• Yoshida I, Shiba T, Taniguchi H, et al. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1483–1489. PubMed PMID: 25030237; eng.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005 Jun;112(6):1048–1053. PubMed PMID: 15885778; eng.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006 Apr;113(4):623.e1. PubMed PMID: 16581423; eng.
   Web of Science ®Google Scholar
• Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006 Apr;113(4):633.e1–4. PubMed PMID: 16483659; eng.
   Web of Science ®Google Scholar
• Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012 May;119(5):992–1000. PubMed PMID: 22424834; eng.
   PubMed Web of Science ®Google Scholar
• Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013 Feb;120(2):349–354. PubMed PMID: 23131717; eng.
   PubMed Web of Science ®Google Scholar
• Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009 Jul;148(1):43–58.e1. PubMed PMID: 19376495; eng.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432–1444. PubMed PMID: 17021319.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015 Feb;99(2):220–226. PubMed PMID: 25193672; PubMed Central PMCID: PMCPMC4316940.
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012 May;119(5):1001–1010. PubMed PMID: 22444829; eng.
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013 May;120(5):1046–1056. PubMed PMID: 23352196; eng.
   PubMed Web of Science ®Google Scholar
• Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010 Sep;150(3):315–324.e1. PubMed PMID: 20598667; eng
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011 May;118(5):831–839. PubMed PMID: 21146229; eng.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015 Dec;122(12):2514–2522. PubMed PMID: 26391465; eng.
   PubMed Web of Science ®Google Scholar
• Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018 Jan;125(1):57–65. PubMed PMID: 28893454; eng.
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013 Nov;120(11):2292–2299. PubMed PMID: 23642856.
   PubMed Web of Science ®Google Scholar
• Yasunari T, Shiraki K, Hattori H, et al. Frequency of choroidal abnormalities in neurofibromatosis type 1. Lancet. 2000 Sep 16;356(9234):988–992. PubMed PMID: 11041400.
   PubMed Web of Science ®Google Scholar
• A phase III study to evaluate the port delivery system implant with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration (Archway). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03677934?term=ranibizumab&cond=Macular+Degeneration&phase=2&draw=2&rank=12
   Google Scholar
• Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014 Nov;121(11):2181–2192. PubMed PMID: 25015215; eng.
   PubMed Web of Science ®Google Scholar
• Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):130–139. PubMed PMID: 23021093; eng.
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012 Jun;119(6):1175–1183. PubMed PMID: 22306121; eng.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009 Sep;116(9):1731–1739. PubMed PMID: 19643495; eng.
   PubMed Web of Science ®Google Scholar
• Holz FG, Bandello F, Gillies M, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013 Sep;97(9):1161–1167. PubMed PMID: 23850682; PubMed Central PMCID: PMCPMC3756427. eng.
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Jama. 1997 Jul 2;278(1):51–57. PubMed PMID: 9207339
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399–1411. PubMed PMID: 22578446; eng.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388–1398. PubMed PMID: 22555112; PubMed Central PMCID: PMCPMC3389193. eng.
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013 Nov;120(11):2300–2309. PubMed PMID: 23916488; eng.
   PubMed Web of Science ®Google Scholar
• Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146–152. PubMed PMID: 25227499; eng.
   PubMed Web of Science ®Google Scholar
• Berg K, Hadzalic E, Gjertsen I, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016 Jan;123(1):51–59. PubMed PMID: 26477842; eng.
   PubMed Web of Science ®Google Scholar
• Vottonen P, Kankaanpaa E. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio university hospital in Finland based on a two-eye Markov transition model. Acta Ophthalmol. 2016 Nov;94(7):652–656. PubMed PMID: 27481048; eng
   PubMed Web of Science ®Google Scholar
• Elshout M, van der Reis MI, Webers CA, et al. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2014 Dec;252(12):1911–1920. PubMed PMID: 24777708; eng.
   Google Scholar
• Ayata A, Unal M, Ersanli D, et al. Near infrared fluorescence and OCT features of choroidal abnormalities in type 1 neurofibromatosis. Clin Exp Ophthalmol. 2008 May;36(4):390–392. PubMed PMID: 18700931.
   PubMed Web of Science ®Google Scholar
• 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02140151?term=NCT02140151&rank=1
   Google Scholar
• NCT03071055. 2018. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT03071055&cntry=&state=&city=&dist=
   Google Scholar
• Extension Study for the Port Delivery System With Ranibizumab (Portal) (Portal). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03683251
   Google Scholar
• Evaluation of the usefulness of a treat and extend regimen using ranibizumab for neovascular AMD. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02321839?term=NCT02321839&rank=1
   Google Scholar
• Comparison of PDT combination with ranibizumab vs. ranibizumab monotherapy in persistent PCV with initial loading dose. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02864472?term=NCT02864472&rank=1
   Google Scholar
• Okada M, Kandasamy R, Chong EW, et al. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol. 2018 Aug;192:184–197. PubMed PMID: 29885297; eng.
   PubMed Web of Science ®Google Scholar
• Chen YN, Powell AM, Mao A, et al. Retrospective review of lucentis “Treat and extend” patterns and outcomes in age-related macular degeneration. Retina. 2016 Feb;36(2):272–278. PubMed PMID: 26200511; eng.
   PubMed Web of Science ®Google Scholar
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02510794
   Google Scholar
• A phase III study to evaluate the port delivery system implant with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration (Archway) (Archway). 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03677934?term=NCT03677934&rank=1
   Google Scholar